"Pheochromocytoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)
Descriptor ID |
D010673
|
MeSH Number(s) |
C04.557.465.625.650.700.725 C04.557.580.625.650.700.725
|
Concept/Terms |
Pheochromocytoma, Extra-Adrenal- Pheochromocytoma, Extra-Adrenal
- Extra-Adrenal Pheochromocytoma
- Extra-Adrenal Pheochromocytomas
- Pheochromocytoma, Extra Adrenal
- Pheochromocytomas, Extra-Adrenal
|
Below are MeSH descriptors whose meaning is more general than "Pheochromocytoma".
Below are MeSH descriptors whose meaning is more specific than "Pheochromocytoma".
This graph shows the total number of publications written about "Pheochromocytoma" by people in this website by year, and whether "Pheochromocytoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 3 | 0 | 3 |
1995 | 4 | 0 | 4 |
1996 | 1 | 2 | 3 |
1997 | 0 | 1 | 1 |
1998 | 2 | 2 | 4 |
1999 | 2 | 0 | 2 |
2000 | 1 | 0 | 1 |
2002 | 2 | 1 | 3 |
2003 | 2 | 2 | 4 |
2004 | 3 | 0 | 3 |
2005 | 2 | 0 | 2 |
2006 | 2 | 0 | 2 |
2007 | 4 | 1 | 5 |
2008 | 5 | 2 | 7 |
2009 | 3 | 1 | 4 |
2010 | 7 | 2 | 9 |
2011 | 5 | 0 | 5 |
2012 | 3 | 0 | 3 |
2013 | 7 | 0 | 7 |
2014 | 2 | 0 | 2 |
2015 | 3 | 0 | 3 |
2017 | 8 | 0 | 8 |
2018 | 4 | 2 | 6 |
2019 | 5 | 0 | 5 |
2020 | 6 | 0 | 6 |
2021 | 3 | 0 | 3 |
2022 | 6 | 0 | 6 |
2023 | 8 | 0 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pheochromocytoma" by people in Profiles.
-
Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement. Nat Rev Endocrinol. 2024 Mar; 20(3):168-184.
-
Adrenal Neoplasms: Lessons from Adrenal Multidisciplinary Tumor Boards. Radiographics. 2023 07; 43(7):e220191.
-
TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab. 2023 04 13; 108(5):1132-1142.
-
Succinate Dehydrogenase Mutations as Familial Pheochromocytoma Syndromes. Surg Oncol Clin N Am. 2023 04; 32(2):289-301.
-
Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. Lancet Diabetes Endocrinol. 2023 05; 11(5):345-361.
-
Proposed MIBG Scan-Based Tumor Response Criteria of High-Specific-Activity 131 I-MIBG Therapy in Metastatic Pheochromocytoma/Paraganglioma. Clin Nucl Med. 2023 Apr 01; 48(4):320-323.
-
Functional Imaging Evidence of Tumor Response to High-Specific-Activity 131 I-MIBG Therapy in an 84-Year-Old Patient With Metastatic Pheochromocytoma/Paraganglioma. Clin Nucl Med. 2023 May 01; 48(5):426-427.
-
Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma. Endocr Relat Cancer. 2023 02 01; 30(2).
-
The prevalence and spectrum of reported incidental adrenal abnormalities in abdominal computed tomography of cancer patients: The experience of a comprehensive cancer center. Front Endocrinol (Lausanne). 2022; 13:1023220.
-
American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary. JAMA Surg. 2022 10 01; 157(10):870-877.